

Special Issue

Advances in the Diagnosis, Treatment and Prognosis of Hepatocellular Carcinoma

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the third leading cause of death worldwide, and its incidence is expected to rise significantly in the coming years because of the Westernization taking place around the world. In fact, the growing impact of metabolic disease has reshaped the feature of hepatology. Metabolic-associated fatty liver disease (MAFLD) has become the leading cause of liver cirrhosis and HCC. The latter can occur also in the absence of cirrhotic evolution of hepatic disease. Thus, early HCC diagnosis is a must for clinical and bench research. Over anti-angiogenetic treatment, HCC prognosis and life expectancy are improved by the use of check-point inhibitors. However, the lack of a genetic mutation fingerprint of HCC requires newer biomarkers for more personalized medicine. In this context, the growing role of gut microbiota dysbiosis in liver disease and in HCC physiopathology can be an efficacious tool in the diagnostic and therapeutic armamentarium.

Guest Editor

Dr. Emdio Scarpellini

Departement Chronische Ziekten, Metabolisme en Veroudering,
Leuven, Belgium

Deadline for manuscript submissions

closed (15 May 2025)



Medicina

an Open Access Journal
Published by MDPI

Impact Factor 2.4
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/146353

Medicina
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicina@mdpi.com

[mdpi.com/journal/
medicina](https://mdpi.com/journal/medicina)





Medicina

an Open Access Journal
Published by MDPI

Impact Factor 2.4
CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/
medicina](https://mdpi.com/journal/medicina)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius
Medical Academy, Lithuanian University of Health Sciences, Kaunas,
Lithuania

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)